FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER

被引:0
作者
Yildirim, Emine [1 ]
Bektas, Sibel [2 ]
Goktas Aydin, Sabin [3 ]
Muzaffer, Ahmet E. R. [1 ]
Yanik, Irem [2 ]
Gumuskaya, Perihan Ozkan [4 ]
Yilmaz, Barbaros Utku [1 ]
Bilici, Ahmet [3 ]
Oncel, Mustafa [5 ]
机构
[1] Univ Hlth Sci, Gaziosmanpasa Training & Res Hosp, Dept Gen Surg, Istanbul, Turkey
[2] Univ Hlth Sci, Gaziosmanpasa Training & Res Hosp, Dept Pathol, Istanbul, Turkey
[3] Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey
[4] Univ Hlth Sci, Prof Dr Cemil Tascioglu City Hosp, Dept Internal Med, Istanbul, Turkey
[5] Medipol Univ, Fac Med, Dept Gen Surg, Istanbul, Turkey
来源
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI | 2022年
关键词
Local advanced gastric cancer; neoadjuvant chemotherapy response; pathological complete response; perineural invasion; LYMPH-NODE METASTASIS; PHASE-II TRIAL; GASTROESOPHAGEAL ADENOCARCINOMA; PERIOPERATIVE CHEMOTHERAPY; PRETREATMENT NEUTROPHIL; OPEN-LABEL; SURGERY; RATIO; CAPECITABINE; FLUOROURACIL;
D O I
10.26650/IUITFD.2021.950751
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: In the treatment of local advanced gastric cancer (LAGC), it is recommended to start with neoadjuvant chemotherapy (NAC). Although the benefits of NAC have been shown, it is still not fully understood which patients respond better. The aim of this study was to investigate the effect of hematological and histopathological parameters on the response to chemotherapy. Material and Method: A retrospective examination was made of 38 patients who underwent surgery for LAGC after receiving NAC. Evaluations were made by comparing the demographic characteristics, histopathological characteristics in an endoscopic biopsy of the tumor, preoperative hemoglobin levels, and neutrophil-lymphocyte ratios with the postoperative pathological response to determine which tumor characteristics gave a better response. Results: In the postoperative histopathological evaluation, there was a pathological complete response to chemotherapy in two patients (6%), grade 1 in 9 patients (24%), grade 2 in 13 patients (34%), and grade 3 in 14 patients (36%). A statistically significant relationship was determined between the histopathological absence of perineural invasion and pathological complete response (p=0.023). Conclusion: A relationship between perineural invasion and poor response to chemotherapy was determined. Although not at a statistically significant level, there was also observed to be a poor response to chemotherapy in the presence of low grade and lymphovascular invasion.
引用
收藏
页数:10
相关论文
共 40 条
[1]   Predictive Value of Baseline Neutrophil/Lymphocyte Ratio for T4 Disease in Wall-Penetrating Gastric Cancer [J].
Aizawa, Masaki ;
Gotohda, Naoto ;
Takahashi, Shinichiro ;
Konishi, Masaru ;
Kinoshita, Taira .
WORLD JOURNAL OF SURGERY, 2011, 35 (12) :2717-2722
[2]   Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma [J].
Ajani, JA ;
Mansfield, PF ;
Janjan, N ;
Morris, J ;
Pisters, PW ;
Lynch, PM ;
Feig, B ;
Myerson, R ;
Nivers, R ;
Cohen, DS ;
Gunderson, LL .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2774-2780
[3]   Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma [J].
Ajani, JA ;
Mansfield, PF ;
Lynch, PM ;
Pisters, PW ;
Feig, B ;
Dumas, P ;
Evans, DB ;
Raijman, I ;
Hargraves, K ;
Curley, S ;
Ota, DM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2403-2411
[4]   Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response [J].
Ajani, Jaffer A. ;
Winter, Kathryn ;
Okawara, Gordon S. ;
Donohue, John H. ;
Pisters, Peter W. T. ;
Crane, Christopher H. ;
Greskovich, John F. ;
Anne, P. Rani ;
Bradley, Jeffrey D. ;
Willett, Christopher ;
Rich, Tyvin A. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3953-3958
[5]   Gastric Cancer, Version 3.2016 [J].
Ajani, Jaffer A. ;
D'Amico, Thomas A. ;
Almhanna, Khaldoun ;
Bentrem, David J. ;
Chao, Joseph ;
Das, Prajnan ;
Denlinger, Crystal S. ;
Fanta, Paul ;
Farjah, Farhood ;
Fuchs, Charles S. ;
Gerdes, Hans ;
Gibson, Michael ;
Glasgow, Robert E. ;
Hayman, James A. ;
Hochwald, Steven ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Jaroszewski, Dawn ;
Johung, Kimberly L. ;
Keswani, Rajesh N. ;
Kleinberg, Lawrence R. ;
Korn, W. Michael ;
Leong, Stephen ;
Linn, Catherine ;
Lockhart, A. Craig ;
Ly, Quan P. ;
Mulcahy, Mary F. ;
Orringer, Mark B. ;
Perry, Kyle A. ;
Poultsides, George A. ;
Scott, Walter J. ;
Strong, Vivian E. ;
Washington, Mary Kay ;
Weksler, Benny ;
Willett, Christopher G. ;
Wright, Cameron D. ;
Zelman, Debra ;
McMillian, Nicole ;
Sundar, Hema .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1286-1312
[6]   Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Hofheinz, Ralf D. ;
Pauligk, Claudia ;
Kopp, Hans-Georg ;
Haag, Georg Martin ;
Luley, Kim Barbara ;
Meiler, Johannes ;
Homann, Nils ;
Lorenzen, Sylvie ;
Schmalenberg, Harald ;
Probst, Stephan ;
Koenigsmann, Michael ;
Egger, Matthias ;
Prasnikar, Nicole ;
Caca, Karel ;
Trojan, Joerg ;
Martens, Uwe M. ;
Block, Andreas ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Clemens, Michael ;
Illerhaus, Gerald ;
Zirlik, Katja ;
Behringer, Dirk M. ;
Schmiegel, Wolff ;
Pohl, Michael ;
Heike, Michael ;
Ronellenfitsch, Ulrich ;
Schuler, Martin ;
Bechstein, Wolf O. ;
Koenigsrainer, Alfred ;
Gaiser, Timo ;
Schirmacher, Peter ;
Hozaeel, Wael ;
Reichart, Alexander ;
Goetze, Thorsten O. ;
Sievert, Mark ;
Jaeger, Elke ;
Moenig, Stefan ;
Tannapfel, Andrea .
LANCET ONCOLOGY, 2016, 17 (12) :1697-1708
[7]   Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Kim, Young-Woo ;
Yang, Han-Kwang ;
Chung, Hyun Cheol ;
Park, Young-Kyu ;
Lee, Kyung Hee ;
Lee, Keun-Wook ;
Kim, Yong Ho ;
Noh, Sang-Ik ;
Cho, Jae Yong ;
Mok, Young Jae ;
Kim, Yeul Hong ;
Ji, Jiafu ;
Yeh, Ta-Sen ;
Button, Peter ;
Sirzen, Florin ;
Noh, Sung Hoon .
LANCET, 2012, 379 (9813) :315-321
[8]   HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology [J].
Bartley, Angela N. ;
Washington, Mary Kay ;
Ventura, Christina B. ;
Ismaila, Nofisat ;
Colasacco, Carol ;
Benson, Al B., III ;
Carrato, Alfredo ;
Gulley, Margaret L. ;
Jain, Dhanpat ;
Kakar, Sanjay ;
Mackay, Helen J. ;
Streutker, Catherine ;
Tang, Laura ;
Troxell, Megan ;
Ajani, Jaffer A. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (12) :1345-1363
[9]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[10]   A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer [J].
Brenner, B. ;
Shah, M. A. ;
Karpeh, M. S. ;
Gonen, M. ;
Brennan, M. F. ;
Coit, D. G. ;
Klimstra, D. S. ;
Tang, L. H. ;
Kelsen, D. P. .
ANNALS OF ONCOLOGY, 2006, 17 (09) :1404-1411